In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

According to brokerage Jefferies, the average drug development cycle spans 8 to 10 years, with success rates below 10% and ...

AI-generated Trump video dupes people, India’s first AI blood test, new features for shopping, weather forecasting, reducing ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Every healthcare company claims to be working in the patient's best interest, and yet prices only seem to rise.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

The global Drug Discovery Software market valued at ~$2 billion in 2020 and is expected to grow at a CAGR of ~14% to cross $3.5 billion by 2025, driven by growing R&D spending across the world, need ...

Technical decisions that advance inference capabilities can help deliver the promise of ubiquitous, accessible AI.

The internet freaked out after Anthropic revealed that Claude attempts to report “immoral” activity to authorities under ...

Nvidia (NASDAQ: NVDA) has been the top AI investment since the AI arms race kicked off in 2023. Over that time frame, ...

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting (ASCO), scheduled to take place ...